| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e664bf06cd946d8dc923ab5e33cd43f9 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D471-04 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D471-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-496
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5377
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-541 |
| filingDate |
2017-09-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4713b6c5f07ad0f1d73b8251e8478aee |
| publicationDate |
2018-07-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CN-108341815-A |
| titleOfInvention |
A kind of inhibition kinases compound and application thereof |
| abstract |
A kind of inhibition kinases compound and application thereof.The present invention provides formula (I) compound, its stereoisomer, tautomer or pharmaceutically acceptable salt, it is as FGFR4 Kinase Selectivities inhibitor and its is preparing treatment by the application in the drug or pharmaceutical composition of FGFR4 or FGF19 associated diseases, compound disclosed by the invention is with a wide range of applications to the selective remarkable inhibiting activities of FGFR4 in therapeutic field of tumor. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-113072550-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-112513037-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-113072550-B
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2020020377-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022089648-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11136320-B2 |
| priorityDate |
2017-01-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |